结核病治疗中对贝达喹啉和地拉马尼的获得性耐药性。
Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
作者信息
Bloemberg Guido V, Keller Peter M, Stucki David, Trauner Andrej, Borrell Sonia, Latshang Tsogyal, Coscolla Mireia, Rothe Thomas, Hömke Rico, Ritter Claudia, Feldmann Julia, Schulthess Bettina, Gagneux Sebastien, Böttger Erik C
机构信息
University of Zurich, Zurich, Switzerland.
出版信息
N Engl J Med. 2015 Nov 12;373(20):1986-8. doi: 10.1056/NEJMc1505196.
Abstract
Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.
摘要
耐多药结核分枝杆菌的治疗是一项挑战。这封信描述了对新疗法——贝达喹啉和地拉曼尼产生耐药性的情况。
相似文献
1
Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
N Engl J Med. 2015 Nov 12;373(20):1986-8. doi: 10.1056/NEJMc1505196.
2
Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Lancet Respir Med. 2017 Oct;5(10):772-774. doi: 10.1016/S2213-2600(17)30309-0. Epub 2017 Sep 5.
3
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Clin Infect Dis. 2019 Sep 13;69(7):1229-1231. doi: 10.1093/cid/ciz074.
4
Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
Lancet Infect Dis. 2019 May;19(5):470. doi: 10.1016/S1473-3099(19)30168-9.
5
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
Eur Respir J. 2018 Jul 4;52(1). doi: 10.1183/13993003.00934-2018. Print 2018 Jul.
6
Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
Clin Infect Dis. 2021 Dec 16;73(12):2329-2331. doi: 10.1093/cid/ciaa1064.
7
Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
Eur Respir J. 2019 Jan 10;53(1). doi: 10.1183/13993003.01154-2018. Print 2019 Jan.
8
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Lancet Infect Dis. 2021 Jul;21(7):975-983. doi: 10.1016/S1473-3099(20)30770-2. Epub 2021 Feb 12.
9
Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
Emerg Infect Dis. 2023 May;29(5):1081-1084. doi: 10.3201/eid2905.221716.
10
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Lancet Infect Dis. 2018 May;18(5):536-544. doi: 10.1016/S1473-3099(18)30100-2. Epub 2018 Feb 13.
引用本文的文献
1
Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study.
Lancet Reg Health Eur. 2025 Jul 15;56:101380. doi: 10.1016/j.lanepe.2025.101380. eCollection 2025 Sep.
2
Ration or compassion? Stakeholder perspectives on the introduction of bedaquiline in South Africa.
PLOS Glob Public Health. 2025 Jul 18;5(7):e0004821. doi: 10.1371/journal.pgph.0004821. eCollection 2025.
3
Structure and assembly of the MmpL5/MmpS5 efflux transporter from Mycobacterium tuberculosis.
Nat Commun. 2025 May 29;16(1):4976. doi: 10.1038/s41467-025-60365-5.
4
as a model for understanding principles of mycobacterial pathogenesis.
J Bacteriol. 2025 May 22;207(5):e0004725. doi: 10.1128/jb.00047-25. Epub 2025 Apr 30.
5
Sulfate Ester Dioxygenase Rv3406 Is Able to Inactivate the RCB18350 Compound.
ACS Infect Dis. 2025 Apr 11;11(4):986-997. doi: 10.1021/acsinfecdis.4c01030. Epub 2025 Mar 20.
6
High Prevalence of atpE Mutations in Bedaquiline-Resistant Mycobacterium tuberculosis Isolates, Russia.
Emerg Infect Dis. 2025 Mar;31(3):525-536. doi: 10.3201/eid3103.241488.
7
Anti-Mycobacterial Activity of Bacterial Topoisomerase Inhibitors with Dioxygenated Linkers.
ACS Infect Dis. 2025 Feb 14;11(2):474-482. doi: 10.1021/acsinfecdis.4c00743. Epub 2025 Jan 10.
8
Editorial: Factors associated with drug resistance and virulence of .
Front Cell Infect Microbiol. 2024 Dec 19;14:1504923. doi: 10.3389/fcimb.2024.1504923. eCollection 2024.
9
Mice infected with . with mutations still benefit from bedaquiline treatment.
IJTLD Open. 2024 Nov 1;1(11):525-527. doi: 10.5588/ijtldopen.23.0527. eCollection 2024 Nov.
10
Chrysomycins, Anti-Tuberculosis C-Glycoside Polyketides from sp. MS751.
Mar Drugs. 2024 Jun 3;22(6):259. doi: 10.3390/md22060259.
本文引用的文献
1
Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options.
Lancet Infect Dis. 2014 Nov;14(11):1136-1149. doi: 10.1016/S1473-3099(14)70828-X. Epub 2014 Sep 1.
2
Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients.
J Infect Dis. 2012 Dec 1;206(11):1724-33. doi: 10.1093/infdis/jis601. Epub 2012 Sep 14.
3
Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes.
Nat Genet. 2011 Dec 18;44(1):106-10. doi: 10.1038/ng.1038.
4
Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis.
Mol Microbiol. 2010 Aug;77(4):830-40. doi: 10.1111/j.1365-2958.2010.07218.x. Epub 2010 Jun 1.
Zotero 插件